Content not available. Please visit the original article.
Lilly Bets Big on In Vivo CAR-T as Korean Firms Accelerate Development
[Aggressive Investment from Global Big Pharma] First Clinical Trial Cures Three Patients with Single Injection Eli Lilly Invests 13 Trillion Won This Year Alone Big Pharma Firms Pursue Back-to-Back M&A Deals AbClon Builds Platform with Strike Pharma Rznomics Secures Proprietary Delivery Technology
Finance||
By Park Hyo-jung
AI-translated from Korean. Quotes from foreign sources are based on Korean-language reports and may not reflect exact original wording.